{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:40:13Z","timestamp":1789828813548,"version":"4.0.1"},"reference-count":185,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed.<\/jats:p>","DOI":"10.3390\/ph5020209","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T11:11:43Z","timestamp":1329390703000},"page":"209-235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Structure Based Antibody-Like Peptidomimetics"],"prefix":"10.3390","volume":"5","author":[{"given":"Ramachandran","family":"Murali","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cedars-Sinai Medical Center, D5091 Davis Building, 8700 Beverly Blvd., Los Angeles, CA 90048, USA"},{"name":"Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0165-6147(96)01011-5","article-title":"Recombinant proteins for therapy","volume":"17","author":"Buckel","year":"1996","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13238-010-0052-8","article-title":"Monoclonal antibodies\u2014A proven and rapidly expanding therapeutic modality for human diseases","volume":"1","author":"An","year":"2010","journal-title":"Protein Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1876837","article-title":"Design and synthesis of a mimetic from an antibody complementarity-determining region","volume":"253","author":"Saragovi","year":"1991","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/(SICI)1097-0282(1998)47:1<93::AID-BIP10>3.0.CO;2-H","article-title":"Novel miniproteins engineered by the transfer of active sites to small natural scaffolds","volume":"47","author":"Vita","year":"1998","journal-title":"Biopolymers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.cbpa.2005.10.015","article-title":"Molecular recognition with designed peptides and proteins","volume":"9","author":"Cooper","year":"2005","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/13543784.16.5.595","article-title":"Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins","volume":"16","author":"Craik","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4161\/mabs.3.5.17334","article-title":"Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"MAbs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.copbio.2009.10.010","article-title":"Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology","volume":"20","author":"Huang","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.copbio.2011.06.002","article-title":"Non-immunoglobulin based protein scaffolds","volume":"22","author":"Lofblom","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0167-7799(93)90018-5","article-title":"Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents","volume":"11","author":"Bristow","year":"1993","journal-title":"Trends Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1126\/science.6337396","article-title":"Human insulin from recombinant DNA technology","volume":"219","author":"Johnson","year":"1983","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0958-1669(96)80073-5","article-title":"The promise and pitfalls of monoclonal antibody therapeutics","volume":"7","author":"Berkower","year":"1996","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/hum.1994.5.7-809","article-title":"In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice","volume":"5","author":"Elkins","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0952-7915(99)00013-8","article-title":"Recombinant antibody constructs in cancer therapy","volume":"11","author":"Hudson","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"ref_15","unstructured":"Jones, D.R. (1993). Design and Synthesis of Nonpeptide Peptidomimetic Enzyme Inhibitors, and Synthesis and Characterization of C60O, the First Buckminsterfullerene Epoxide, Graduate School of Arts and Sciences, University of Pennsylvania."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H","article-title":"Phase I\/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma","volume":"85","author":"Juweid","year":"1999","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0959-440X(00)00108-1","article-title":"Engineering therapeutic proteins","volume":"10","author":"McCafferty","year":"2000","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0167-7799(96)10024-X","article-title":"Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations","volume":"14","author":"Cho","year":"1996","journal-title":"Trends Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0192-0561(92)90169-L","article-title":"Pre-clinical toxicity of IL-4: A model for studying protein therapeutics","volume":"14","author":"Dean","year":"1992","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nbt0298-153","article-title":"Improving protein therapeutics with sustained-release formulations","volume":"16","author":"Putney","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1023\/A:1016084508097","article-title":"Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution","volume":"13","author":"Takakura","year":"1996","journal-title":"Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0300-483X(95)03122-V","article-title":"Recent developments and perspectives of biotechnology-derived products","volume":"105","author":"Thomas","year":"1995","journal-title":"Toxicology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2004.10.011","article-title":"Overview of monoclonal antibodies in cancer therapy: Present and promise","volume":"54","author":"Stern","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4161\/cbt.3.4.790","article-title":"Targeting of radio-isotopes for cancer therapy","volume":"3","author":"Milenic","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.4049\/jimmunol.162.6.3663","article-title":"Elimination of the immunogenicity of therapeutic antibodies","volume":"162","author":"Gilliland","year":"1999","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0167-5699(00)01680-7","article-title":"Antibody humanization: A case of the \u2018Emperor\u2019s new clothes\u2019?","volume":"21","author":"Clark","year":"2000","journal-title":"Immunol. Today"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/157488610792246055","article-title":"Safety of therapeutic monoclonal antibodies","volume":"5","author":"Niebecker","year":"2010","journal-title":"Curr. Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/157488610792246037","article-title":"Immunotoxicity and immunogenicity of biopharmaceuticals: Design concepts and safety assessment","volume":"5","author":"Bhogal","year":"2010","journal-title":"Curr. Drug. Saf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jmr.300070103","article-title":"The making of the minibody: An engineered beta-protein for the display of conformationally constrained peptides","volume":"7","author":"Tramontano","year":"1994","journal-title":"J. Mol. Recognit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jmb.2007.12.001","article-title":"Peptide mimic of the HIV envelope gp120-gp41 interface","volume":"376","author":"Kim","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/prot.20275","article-title":"Computational studies and peptidomimetic design for the human p53-MDM2 complex","volume":"58","author":"Zhong","year":"2005","journal-title":"Proteins"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0006-291X(03)01131-8","article-title":"A peptide mimetic of an anti-CD4 monoclonal antibody by rational design","volume":"307","author":"Casset","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1097-2765(03)00138-2","article-title":"\u03b1v\u03b25 Integrin-dependent programmed cell death triggered by a peptide mimic of annexin V","volume":"11","author":"Arap","year":"2003","journal-title":"Mol. Cell."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1021\/jm000034h","article-title":"Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures","volume":"43","author":"Bolin","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nbt0398-267","article-title":"Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation","volume":"16","author":"Fukumoto","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1359-6446(98)01220-3","article-title":"From peptides to drugs via phage display","volume":"3","author":"Kay","year":"1998","journal-title":"Drug Discov. Today"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0923-2494(98)80051-5","article-title":"Peptide mimicry of carbohydrate structures","volume":"149","author":"Phalipon","year":"1998","journal-title":"Res. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1073\/pnas.83.17.6578","article-title":"Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen","volume":"83","author":"Bruck","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0958-1669(97)80065-1","article-title":"Therapeutic peptides and peptidomimetics","volume":"8","author":"Murali","year":"1997","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02786441","article-title":"Structure-based design of immunologically active therapeutic peptides","volume":"17","author":"Murali","year":"1998","journal-title":"Immunol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/exmp.2002.2444","article-title":"Study of disabling T-cell activation and inhibiting T-cell-mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics","volume":"73","author":"Horie","year":"2002","journal-title":"Exp. Mol. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/S0021-9258(19)67772-0","article-title":"Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity","volume":"266","author":"Williams","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nbt0297-150","article-title":"Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes","volume":"15","author":"Zhang","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nbt0496-472","article-title":"Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation","volume":"14","author":"Zhang","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1021\/jm000527m","article-title":"Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis","volume":"44","author":"Berezov","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/72651","article-title":"Rationally designed anti-HER2\/neu peptide mimetic disables P185HER2\/neu tyrosine kinases in vitro and in vivo","volume":"18","author":"Park","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.bmcl.2011.02.013","article-title":"Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent","volume":"21","author":"Ponde","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_50","first-page":"309","article-title":"The immunoglobulin fold. Structural classification, sequence patterns and common core","volume":"242","author":"Bork","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/protein\/12.7.563","article-title":"The immunoglobulin fold family: Sequence analysis and 3D structure comparisons","volume":"12","author":"Halaby","year":"1999","journal-title":"Protein Eng."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1042\/BST0370751","article-title":"The evolution of protein domain families","volume":"37","author":"Buljan","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1000481","DOI":"10.1371\/journal.ppat.1000481","article-title":"Immunoglobulin superfamily virus receptors and the evolution of adaptive immunity","volume":"5","author":"Dermody","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref_54","unstructured":"Schrodinger, L.L.C. (2010). The PyMOL Molecular Graphics System, Version 1.3r1, Schrodinger LLC."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-2836(77)80200-3","article-title":"The protein data bank: A computer-based archival file for macromolecular structures","volume":"112","author":"Bernstein","year":"1977","journal-title":"J. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1006\/jmbi.1996.0548","article-title":"Antibody-antigen interactions: contact analysis and binding site topography","volume":"262","author":"MacCallum","year":"1996","journal-title":"J. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/342877a0","article-title":"Conformations of immunoglobulin hypervariable regions","volume":"342","author":"Chothia","year":"1989","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1073\/pnas.91.3.1089","article-title":"Bound water molecules and conformational stabilization help mediate an antigen-antibody association","volume":"91","author":"Bhat","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1074\/jbc.270.30.18067","article-title":"Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme","volume":"270","author":"Lescar","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0167-7799(94)90083-3","article-title":"Antibody design: Beyond the natural limits","volume":"12","author":"Rees","year":"1994","journal-title":"Trends Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0969-2126(99)80049-5","article-title":"A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops","volume":"7","author":"Decanniere","year":"1999","journal-title":"Structure"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/bi991830w","article-title":"Camelid heavy-chain variable domains provide efficient combining sites to haptens","volume":"39","author":"Spinelli","year":"2000","journal-title":"Biochemistry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/protein\/4.7.773","article-title":"Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation","volume":"4","author":"Kettleborough","year":"1991","journal-title":"Protein Eng."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1006\/jmbi.1993.1638","article-title":"Crystallization of single-chain Fv proteins","volume":"234","author":"Essig","year":"1993","journal-title":"J. Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12918","DOI":"10.1021\/bi9810407","article-title":"Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment","volume":"37","author":"Arndt","year":"1998","journal-title":"Biochemistry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/protein\/13.8.565","article-title":"ScFv multimers of the anti-neuraminidase antibody NC10: Shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers","volume":"13","author":"Dolezal","year":"2000","journal-title":"Protein Eng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"Diabodies\u201d: Small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1432-1033.1994.tb18724.x","article-title":"Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment\/sialidase complex","volume":"221","author":"Kortt","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1021\/bi00177a021","article-title":"Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy","volume":"33","author":"Freund","year":"1994","journal-title":"Biochemistry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1096\/fasebj.9.1.7821762","article-title":"Single-chain Fvs","volume":"9","author":"Raag","year":"1995","journal-title":"FASEB J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jnci\/82.14.1191","article-title":"In vivo tumor targeting of a recombinant single-chain antigen-binding protein","volume":"82","author":"Colcher","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/08830189309061696","article-title":"Medical applications of single-chain antibodies","volume":"10","author":"Huston","year":"1993","journal-title":"Int. Rev. Immunol."},{"key":"ref_73","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semnuclmed.2009.12.005","article-title":"Antibody vectors for imaging","volume":"40","author":"Olafsen","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08820139.2010.542228","article-title":"Nanobody; an old concept and new vehicle for immunotargeting","volume":"40","author":"Rahbarizadeh","year":"2011","journal-title":"Immunol. Invest."},{"key":"ref_76","first-page":"176","article-title":"Alternative antibody formats","volume":"12","author":"Kontermann","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_77","first-page":"543","article-title":"Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles","volume":"13","author":"Mabry","year":"2010","journal-title":"IDrugs"},{"key":"ref_78","first-page":"340","article-title":"Cancer therapy with bispecific antibodies: Clinical experience","volume":"12","author":"Thakur","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: Hope and hype","volume":"2","author":"Nelson","year":"2010","journal-title":"MAbs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s001099900038","article-title":"The biology of the 17-1A antigen (Ep-CAM)","volume":"77","author":"Balzar","year":"1999","journal-title":"J. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3810\/pgm.1999.10.1.703","article-title":"New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs","volume":"106","author":"Fye","year":"1999","journal-title":"Postgrad. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0958-1669(98)80014-1","article-title":"Recombinant antibody fragments","volume":"9","author":"Hudson","year":"1998","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1126\/science.2047874","article-title":"Monoclonal antibodies in diagnosis and therapy","volume":"252","author":"Waldmann","year":"1991","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0161-5890(90)90070-G","article-title":"Anti-idiotypic antibodies of a predefined specificity generated against CDR3VH synthetic peptides define a private anti-CD4 idiotype","volume":"27","author":"Attanasio","year":"1990","journal-title":"Mol. Immunol."},{"key":"ref_85","first-page":"879","article-title":"Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy","volume":"45","author":"Schroff","year":"1985","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4049\/jimmunol.135.2.1530","article-title":"Human immune response to multiple injections of murine monoclonal IgG","volume":"135","author":"Shawler","year":"1985","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/protein\/9.10.895","article-title":"A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing","volume":"9","author":"Roguska","year":"1996","journal-title":"Protein Eng."},{"key":"ref_88","first-page":"575","article-title":"Monoclonal antibodies in the diagnosis and treatment of human diseases","volume":"47","author":"Hamilton","year":"1989","journal-title":"Ann. Biol. Clin. (Paris)"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00007890-199403270-00002","article-title":"CDR-grafted OKT4A monoclonal antibody in cynomolgus renal allograft recipients","volume":"57","author":"Powelson","year":"1994","journal-title":"Transplantation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/349293a0","article-title":"Man-made antibodies","volume":"349","author":"Winter","year":"1991","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1073\/pnas.91.3.969","article-title":"Humanization of murine monoclonal antibodies through variable domain resurfacing","volume":"91","author":"Roguska","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","first-page":"1619","article-title":"Humanization of antibodies","volume":"13","author":"Almagro","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_93","first-page":"6176","article-title":"Improved tumor targeting with chemically cross-linked recombinant antibody fragments","volume":"54","author":"King","year":"1994","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-1119(93)90250-7","article-title":"Peptidomimetics of the immunoglobulin supergene family\u2014A review","volume":"137","author":"Nakanishi","year":"1993","journal-title":"Gene"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0165-6147(94)90049-3","article-title":"Designing peptide mimetics","volume":"15","author":"Moore","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"13612","DOI":"10.1074\/jbc.M110.216812","article-title":"Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways","volume":"286","author":"Vicari","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"18336","DOI":"10.1073\/pnas.1004187107","article-title":"Structural characterization of a beta-turn mimic within a protein-protein interface","volume":"107","author":"Eckhardt","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4049\/jimmunol.161.4.1829","article-title":"Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide","volume":"161","author":"Valadon","year":"1998","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.273.5274.458","article-title":"Small peptides as potent mimetics of the protein hormone erythropoietin","volume":"273","author":"Wrighton","year":"1996","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/bip.360330709","article-title":"Conformational and topographical considerations in the design of biologically active peptides","volume":"33","author":"Hruby","year":"1993","journal-title":"Biopolymers"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1359-6446(97)01062-3","article-title":"Peptidomimetics and small molecule design","volume":"2","author":"Langston","year":"1997","journal-title":"Drug Discov. Today"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00131082","article-title":"Pharmaceutical applications of peptidomimetics","volume":"3","author":"Qabar","year":"1996","journal-title":"Lett. Pept. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1073\/pnas.0401597101","article-title":"Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism","volume":"101","author":"Hasegawa","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389557013407214","article-title":"Modifying TNFalpha for therapeutic use: A perspective on the TNF receptor system","volume":"1","author":"Hasegawa","year":"2001","journal-title":"Mini. Rev. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nbt1197-1266","article-title":"Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF\u03b1 binding to its receptor","volume":"15","author":"Takasaki","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1074\/jbc.M309690200","article-title":"Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo","volume":"279","author":"Cheng","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/0008-5472.CAN-06-1287","article-title":"An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma","volume":"67","author":"Heath","year":"2007","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1073\/pnas.1011686107","article-title":"Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis","volume":"107","author":"Ta","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","first-page":"283","article-title":"Mimicry of viral epitopes with retro-inverso peptides of increased stability","volume":"87","author":"Benkirane","year":"1996","journal-title":"Dev. Biol. Stand."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pro.5560070203","article-title":"Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex","volume":"7","author":"Lombardi","year":"1998","journal-title":"Protein Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.287.5456.1279","article-title":"Convergent solutions to binding at a protein-protein interface","volume":"287","author":"DeLano","year":"2000","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0167-7799(90)90187-3","article-title":"Peptidomimetics and the template approach to nucleation of beta-sheets and alpha-helices in peptides","volume":"8","author":"Kemp","year":"1990","journal-title":"Trends Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1084\/jem.159.5.1502","article-title":"Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide","volume":"159","author":"Chen","year":"1984","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0092-8674(83)90118-6","article-title":"Synthetic idiotypes: The third hypervariable region of murine anti- dextran antibodies","volume":"35","author":"McMillan","year":"1983","journal-title":"Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4049\/jimmunol.144.4.1375","article-title":"Anti-peptide antibodies detect a lupus-related interspecies idiotype that maps to H chain CDR2","volume":"144","author":"Meek","year":"1990","journal-title":"J. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1546293","article-title":"Structural evidence for induced fit as a mechanism for antibody-antigen recognition","volume":"255","author":"Rini","year":"1992","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/j.1460-2075.1994.tb06506.x","article-title":"Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2","volume":"13","author":"Tormo","year":"1994","journal-title":"EMBO J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/aid.1993.9.733","article-title":"Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells","volume":"9","author":"Fecondo","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/bj3020073","article-title":"A synthetic peptide deduced from the sequence in the cross-region of laminin A chain mediates neurite outgrowth, cell attachment and heparin binding","volume":"302","author":"Tashiro","year":"1994","journal-title":"Biochem. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10643","DOI":"10.1073\/pnas.90.22.10643","article-title":"Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library","volume":"90","author":"Yayon","year":"1993","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1073\/pnas.90.22.10638","article-title":"Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library","volume":"90","author":"Balass","year":"1993","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0969-2126(00)00074-5","article-title":"The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody","volume":"2","author":"Malby","year":"1994","journal-title":"Structure"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1126\/science.3368787","article-title":"Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide","volume":"240","author":"Kang","year":"1988","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0165-5728(93)90254-V","article-title":"The structure of a myelin basic protein-associated idiotope","volume":"46","author":"Maier","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0769-2625(85)80111-2","article-title":"A structural basis for the internal image in the idiotypic network: antibodies against synthetic Ab2-D regions cross-react with the original antigen","volume":"136D","author":"Mazza","year":"1985","journal-title":"Ann. Inst. Pasteur Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0021-9258(17)31252-8","article-title":"A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen","volume":"264","author":"Taub","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1016\/S0021-9258(18)42651-8","article-title":"Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells","volume":"267","author":"Taub","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1084\/jem.167.6.1841","article-title":"Do antibodies recognize amino acid side chains of protein antigens independently of the carbon backbone?","volume":"167","author":"Naeve","year":"1988","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.1073\/pnas.85.17.6488","article-title":"Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic\/antireceptor antibody: modeling of their three-dimensional structures","volume":"85","author":"Williams","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","first-page":"93","article-title":"Bioactive Arg-Gly-Asp conformations in anti-integrin GPIIb-IIIa antibodies","volume":"4","author":"Prammer","year":"1994","journal-title":"Receptor"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.4049\/jimmunol.142.12.4392","article-title":"Immune response to a molecularly defined internal image idiotope","volume":"142","author":"Williams","year":"1989","journal-title":"J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1073\/pnas.86.14.5537","article-title":"Development of biologically active peptides based on antibody structure","volume":"86","author":"Williams","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4049\/jimmunol.131.5.2533","article-title":"Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti- idiotypic antibody identifies a cell surface receptor for reovirus","volume":"131","author":"Noseworthy","year":"1983","journal-title":"J. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1073\/pnas.82.5.1494","article-title":"Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptor","volume":"82","author":"Co","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jcb.240280110","article-title":"Anti-idiotypic antibody identifies the cellular receptor of reovirus type 3","volume":"28","author":"Gaulton","year":"1985","journal-title":"J. Cell. Biochem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1098\/rstb.1975.0069","article-title":"Structure and specificity of antibody molecules","volume":"272","author":"Poljak","year":"1975","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12282-007-0018-8","article-title":"Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods","volume":"15","author":"Nakajima","year":"2008","journal-title":"Breast Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jbiosc.2010.02.007","article-title":"Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP","volume":"110","author":"Nakajima","year":"2010","journal-title":"J. Biosci. Bioeng."},{"key":"ref_140","unstructured":"Murali, R. (2004). Unpublished work."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0006-291X(84)90300-0","article-title":"Site-specific antibodies to the erbB oncogene product immunoprecipitate epidermal growth factor receptor","volume":"123","author":"Akiyama","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"ref_144","first-page":"2019","article-title":"Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene","volume":"7","author":"Devilee","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.2885917","article-title":"erbB-2 is a potent oncogene when overexpressed in NIH\/3T3 cells","volume":"237","author":"Pierce","year":"1987","journal-title":"Science"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ijc.2910460708","article-title":"The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer","volume":"5","author":"Gullick","year":"1990","journal-title":"Int. J. Cancer Suppl."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000163601","article-title":"Neu (c-erbB-2), a tumor marker in carcinoma of the female breast","volume":"58","author":"Maguire","year":"1990","journal-title":"Pathobiology"},{"key":"ref_150","first-page":"5184","article-title":"p185neu expression in human lung adenocarcinomas predicts shortened survival","volume":"50","author":"Kern","year":"1990","journal-title":"Cancer Res."},{"key":"ref_151","first-page":"81","article-title":"Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract","volume":"4","author":"Cohen","year":"1989","journal-title":"Oncogene"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000163614","article-title":"Expression of c-erbB-2 in human pancreatic adenocarcinomas","volume":"59","author":"Williams","year":"1991","journal-title":"Pathobiology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0092-8674(85)80050-7","article-title":"Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies","volume":"41","author":"Drebin","year":"1985","journal-title":"Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"9129","DOI":"10.1073\/pnas.83.23.9129","article-title":"Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen","volume":"83","author":"Drebin","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/312545a0","article-title":"Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene","volume":"312","author":"Drebin","year":"1984","journal-title":"Nature"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0076-6879(91)98028-5","article-title":"Cloning, expression, and biological effects of erbB-2\/neu gene in mammalian cells","volume":"198","author":"Segatto","year":"1991","journal-title":"Meth. Enzymol."},{"key":"ref_157","first-page":"1550","article-title":"Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2\/neu gene product","volume":"50","author":"Fendly","year":"1990","journal-title":"Cancer Res."},{"key":"ref_158","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_160","first-page":"1165","article-title":"p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/exmp.1999.2266","article-title":"Shared antigenic epitopes and pathobiological functions of anti-p185her2\/neu monoclonal antibodies","volume":"67","author":"Zhang","year":"1999","journal-title":"Exp. Mol. Pathol."},{"key":"ref_162","unstructured":"Zhang, X. (1997). Structural and functional mapping of immunoglobulin domains. [Ph.D. Dissertation, University of Pennsylvania]."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0968-0896(00)82048-9","article-title":"Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics","volume":"2","author":"Graciani","year":"1994","journal-title":"Bioorg. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1021\/ja963884o","article-title":"Solution structures of Fc epsilon RI alpha-chain mimics: A beta-hairpin peptide and its retroenantiomer","volume":"119","author":"McDonnell","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00918679","article-title":"Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic","volume":"11","author":"Shepard","year":"1991","journal-title":"J. Clin. Immunol."},{"key":"ref_167","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","article-title":"Mechanism of action of trastuzumab and scientific update","volume":"28","author":"Baselga","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"28330","DOI":"10.1074\/jbc.M202880200","article-title":"Disabling receptor ensembles with rationally designed interface peptidomimetics","volume":"277","author":"Berezov","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1038\/sj.onc.1209745","article-title":"AHNP-streptavidin: A tetrameric bacterially produced antibody surrogate fusion protein against p185her2\/neu","volume":"25","author":"Masuda","year":"2006","journal-title":"Oncogene"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nm1378","article-title":"A sensitive and high-throughput assay to detect low-abundance proteins in serum","volume":"12","author":"Zhang","year":"2006","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1073\/pnas.88.4.1266","article-title":"Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program","volume":"88","author":"Cohen","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","first-page":"209","article-title":"Antibody like peptidomimetics as large scale immunodetection probes","volume":"49","author":"Murali","year":"2003","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0889-8588(18)30105-9","article-title":"Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia","volume":"9","author":"Teicher","year":"1995","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1158\/0008-5472.CAN-05-0395","article-title":"A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells","volume":"65","author":"Fantin","year":"2005","journal-title":"Cancer Res."},{"key":"ref_176","first-page":"683","article-title":"Antibodies in the therapy of colon cancer","volume":"26","author":"Welt","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/dna.2005.24.351","article-title":"HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand","volume":"24","author":"Guillemard","year":"2005","journal-title":"DNA Cell Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/sonc.2002.34051","article-title":"Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study","volume":"29","author":"Schneider","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_179","unstructured":"Schneider, J.W. Personal communicatiion."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymeth.2008.05.006","article-title":"Polymersomes: A new multi-functional tool for cancer diagnosis and therapy","volume":"46","author":"Levine","year":"2008","journal-title":"Methods"},{"key":"ref_181","unstructured":"Murali, R., Levine, D.H., and Hammer, D.A. (2008). Unpublished work."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1535-7163.MCT-08-0652","article-title":"Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer","volume":"8","author":"Afshar","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-05-2747","article-title":"Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide","volume":"66","author":"Tan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_184","unstructured":"Murali, R., and Greene, M. (1999). Unpublished work."},{"key":"ref_185","first-page":"489","article-title":"Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins","volume":"5","author":"Wada","year":"1990","journal-title":"Oncogene"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/2\/209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:48:56Z","timestamp":1760219336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/2\/209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,16]]},"references-count":185,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2]]}},"alternative-id":["ph5020209"],"URL":"https:\/\/doi.org\/10.3390\/ph5020209","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,16]]}}}